Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Company news centers on financial and operational results, gross margin and cash flow trends, supply-chain and distribution initiatives, and customer activity tied to dialysis clinics and large dialysis-service providers.
Recurring updates also cover product purchase agreements, expanded delivery capabilities in U.S. regions, additions to the customer clinic footprint, operational changes aimed at improving gross profit, and corporate communications such as earnings release schedules and workplace-related announcements.
Rockwell Medical (Nasdaq:RMTI) renewed and extended its product purchase agreement with aQua Dialysis, a leading independent dialysis provider in Texas. The contract runs for two years with options for two additional one-year renewals.
Rockwell will continue supplying liquid and dry acid and bicarbonate hemodialysis concentrates and other essential dialysis products to aQua Dialysis clinics.
Rockwell Medical (Nasdaq:RMTI) signed a new three-year product purchase agreement with Heritage Dialysis, a Michigan-based provider focused on home dialysis in skilled nursing, assisted living, senior living communities, and patients' homes.
The agreement includes mutual supply and purchasing commitments, options for three additional one-year renewals, and covers Rockwell Medical’s hemodialysis portfolio, including PureCart 720g bicarbonate cartridges, RenalPure liquid acetic-acid concentrate, SteriLyte liquid bicarbonate, and other ancillary dialysis products.
Rockwell Medical (NASDAQ: RMTI) reported Q1 2026 net sales of $17.3M, gross profit of $2.9M and a 17% gross margin. Net loss was $1.6M and Adjusted EBITDA was ($0.3M). Cash and investments totaled $23.9M at March 31, 2026.
The company expects operational changes and pricing to generate >$3M of annualized gross profit improvement and updated 2026 guidance: $70–75M net sales, 18–22% gross margin, $1–2M Adjusted EBITDA, and positive operating cash flow.
Rockwell Medical (Nasdaq: RMTI) will release its first quarter 2026 financial and operational results on Thursday, May 7, 2026. The company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET with replay available.
Speakers include Mark Strobeck, Ph.D., president and CEO, and Jesse Neri, SVP and CFO. The webcast and replay will be available at www.RockwellMed.com/Results and will include discussion of results followed by a Q&A session.
Rockwell Medical (Nasdaq: RMTI) reported fourth-quarter 2025 net sales of $18.3M and full-year net sales of $69.3M. The company was profitable on an Adjusted EBITDA basis for both Q4 and full-year 2025, achieved a Q4 gross margin of 21%, and ended 2025 with $25.0M in cash and investments.
The company extended a major purchase agreement through Dec 31, 2026 with increased pricing, added 30 new western U.S. customers, and issued 2026 guidance targeting $1M–$2M Adjusted EBITDA and positive operating cash flow.
Rockwell Medical (Nasdaq: RMTI) will release fourth-quarter and full-year 2025 results on Thursday, March 26, 2026. A press release will be issued at 6:00 AM ET followed by a live webcast at 8:00 AM ET.
Management speakers include Mark Strobeck, Ph.D., president and CEO, and Jesse Neri, SVP and CFO. The webcast will include discussion of financial and operational results followed by a Q&A. Replay will be available at www.RockwellMed.com/Results.
Rockwell Medical (NASDAQ: RMTI) announced it was certified as a Great Place to Work for the fourth consecutive year on February 12, 2026. The company highlighted employee dedication and said the recognition supports its culture focused on quality, reliability and service for dialysis providers and patients.
Rockwell Medical (Nasdaq: RMTI) reported preliminary unaudited results for Q4 and full-year 2025. The company expects Q4 net sales of ~$18.6M and FY 2025 net sales of ~$69.5M. Q4 gross margin is expected to be ~22%, up from 14% in Q3 2025. Management says the company was cash flow positive in Q4 with operating cash flow of ~$2.3M (the second positive quarter in 2025), and expects cash and investments to increase to ~$25M at December 31, 2025. Results are preliminary, unaudited, and subject to year-end close adjustments.
Rockwell Medical (Nasdaq: RMTI) added 30 new customers in the western United States and reports the Western U.S. now accounts for more than 10% of its customer clinic footprint. The company said this expansion generated multi-million dollars in revenue from the new west coast customer base. Rockwell attributes the growth to rapid scaling of production and expanded logistics after meaningful supply-chain disruption for hemodialysis concentrates in the region. New customers include a large integrated non-profit healthcare system, a California chronic kidney disease and dialysis organization, a community acute care hospital, and an innovation-driven renal care center. The company says it can now more efficiently serve existing customers with facilities in the West and is positioned as an alternative supplier across the continental U.S.
Rockwell Medical (Nasdaq: RMTI) announced that its Amended and Restated Product Purchase Agreement with one of the largest U.S. dialysis providers has been extended through December 31, 2026. The extension includes an increase in product pricing for the extended term. The company said the renewal reflects its reliable supply chain and high-quality hemodialysis products and expressed intent to strengthen and potentially expand the strategic partnership beyond 2026. For additional specifics, Rockwell referenced its Form 8-K filed January 5, 2026.